yimitasvir

Small moleculeexperimental

Clinical trial activity

8 trials · 6 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
4
Phase 3
2
Phase 4
0

Earliest trial started Dec 3, 2014 (NCT03462173)

Timeline

2010s

  1. Jan 1, 2014

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2017

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2018

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4ccc5nc([C@@H]6CCCN6C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]c5c4)c4c3[C@@H]3CC[C@H]4C3)cc2)[nH]1)C(C)C
Mol. weight
855.05 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04565171Phase 1Oct 20, 2020Sichuan University, Sunshine Lake Pharma Co., Ltd.
NCT04552808Phase 1Sep 8, 2020Sunshine Lake Pharma Co., Ltd.
NCT04155515Phase 3Jun 13, 2019TaiGen Biotechnology Co., Ltd.
NCT03487107Phase 3Apr 3, 2018Peking University, Sunshine Lake Pharma Co., Ltd.
NCT03593447Phase 2Mar 15, 2018Peking University, TaiGen Biotechnology Co., Ltd.
NCT03610880Phase 1Oct 17, 2017Central South University, R&G Pharma Studies Co.,Ltd., TaiGen Biotechnology Co., Ltd.
NCT03458481Phase 2Jul 31, 2017Peking University, Sunshine Lake Pharma Co., Ltd.
NCT03462173Phase 1Dec 3, 2014Peking University, Sunshine Lake Pharma Co., Ltd.
Showing 8 of 8 trials
Page 1 / 1

Organizations

Research & Development (6)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Sunshine Lake Pharma Co., Ltd.For profit5532014
Peking UniversityAcademic/Hospital4032014
TaiGen Biotechnology Co., Ltd.For profit3332017
Central South UniversityAcademic/Hospital1012017
R&G Pharma Studies Co.,Ltd.For profit1012017
Sichuan UniversityAcademic/Hospital1012020
6 organizations
Page 1 / 1